Refanezumab
Refanezumab (pronunciation: reh-fan-ez-oo-mab) is a monoclonal antibody designed for the prevention of migraine headaches. It is a biologic medication that targets and binds to the calcitonin gene-related peptide (CGRP), a protein that plays a key role in migraine pathophysiology.
Etymology
The name "Refanezumab" follows the World Health Organization (WHO) guidelines for the naming of monoclonal antibodies. The "-mab" suffix indicates that it is a monoclonal antibody, while the "ezu" infix suggests that it is a humanized antibody. The stem "fane" does not have a specific meaning and is used to create a unique name.
Pharmacology
Refanezumab works by binding to the CGRP, a neuropeptide that is released during a migraine attack. By blocking the action of CGRP, Refanezumab can prevent the onset of a migraine headache. It is administered via intravenous infusion.
Clinical Trials
Refanezumab has been studied in several clinical trials for its efficacy and safety in preventing migraines. The results have shown that it can significantly reduce the frequency of migraine attacks in patients who have a history of chronic migraines.
Side Effects
Common side effects of Refanezumab include nausea, fatigue, and injection site reactions. Serious side effects are rare but can include allergic reactions and changes in blood pressure.
See Also
External links
- Medical encyclopedia article on Refanezumab
- Wikipedia's article - Refanezumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski